| Literature DB >> 34940877 |
Sara N Edmond1,2, Sophia Currie3, Amanda Gehrke4, Caroline G Falker1,5, Minhee Sung1,5, Audrey Abelleira1, Ellen L Edens1,2, William C Becker1,5.
Abstract
Entities:
Mesh:
Substances:
Year: 2022 PMID: 34940877 PMCID: PMC9383145 DOI: 10.1093/pm/pnab348
Source DB: PubMed Journal: Pain Med ISSN: 1526-2375 Impact factor: 3.637
Figure 1.Example of buprenorphine overlap dosing protocol.
Descriptive statistics of survey results
| Question | n | Mean (SD) | Median |
|---|---|---|---|
| 1. How easy was it for you to access your appointment? (5 = very easy, 1 = not easy at all) | 20 | 4.5 (1.00) | 5 |
| 2. How clearly could you hear the ORC members over the phone/video during your appointment? (5 = very clearly, 1 = not clearly at all) | 20 | 4.53 (0.82) | 5 |
| 3. How comfortable did you feel sharing your experiences with the ORC team? (5 = very comfortable, 1 = not comfortable at all) | 20 | 4.25 (1.16) | 5 |
| 4. How comfortable did you feel asking questions during your appointment? (5 = very comfortable, 1 = not comfortable at all) | 20 | 4.26 (1.07) | 5 |
| 5. How well do you feel that the ORC team members listened to you during your appointment? (5 = very well, 1 = not well at all) | 20 | 4.18 (1.04) | 4 |
| 6. How well did you understand your treatment options communicated by the ORC team? (5 = very well, 1 = not well at all). | 18 | 4.22 (1.11) | 5 |
| 7. Have you had any follow-up calls or contact with anyone from the clinic since your intake appointment? If yes, how satisfied were you with the follow-up? (5 = very satisfied, 1 = not satisfied at all) | 5 | 4.40 (0.89) | 5 |
SD = standard deviation.
Smaller n is due to several patients not having follow-up contact at the time of the survey.
Sample characteristics
| Characteristic | M (SD) or % (n) |
|---|---|
| Age, years | 62.9 (11.2) |
| Gender, male | 86.2% (25) |
| Race | |
| White | 82.8% (24) |
| Black | 13.8% (4) |
| Other | 3.4% (1) |
| Referral source | |
| Primary care provider | 79.3% (23) |
| Palliative care | 10.3% (3) |
| Other | 10.3% (3) |
| Opioid use disorder diagnosis, % yes | 3.4% (1) |
| Urine drug toxicology in past 12 months, % yes | 65.5% (19) |
| Health psychology, % with at least one appointment | 34.4% (10) |
| Opioid medication recommendation at intake | |
| Buprenorphine | 58.6% (17) |
| Continued full agonist opioid | 31.0% (9) |
| Other | 10.3% (3) |
| Opioid medication at 30 days after intake | |
| Buprenorphine | 48.3% (14) |
| Continued full agonist opioid | 3.8% (11) |
| Not on buprenorphine or full agonist opioid | 13.8% (4) |
M = mean; SD = standard deviation.